Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anal Cancer Metastatic × Albumin-Bound Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 34 Breast Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Neoplasms 9 Neoplasm Metastasis 8 Lung Neoplasms 4 Esophageal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma 3 Breast Neoplasms, Male 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Recurrence 2 Pancreatic Diseases 2 Metastatic Pancreatic Adenocarcinoma 2 Melanoma 2 Carcinoma 2 Advanced Solid Tumor 2 Tongue Neoplasms 1 Thymus Neoplasms 1 Solid Cancer 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic cancer, adult 1 Ovarian Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡